
She had to fight for help with medical bills. A new California bill could make it easier
In July 2022, the Stockton resident had surgeries to repair an aortic tear and a ruptured blood vessel in her brain and spent two months at Stanford Medical Center, which hosts one of the leading programs in connective tissue disorders like the one Freeman has.
Over the next 18 months, she racked up more than $4 million in medical bills, most of which was paid through her employee health insurance. Her share was $14,343, which she says she'd still be paying if not for Stanford's financial assistance program.
But Stanford, like many hospitals, didn't make it easy for her. It took months of research and persistence on her part before the hospital waived $13,971.
'I feel like I now have the knowledge and power to apply for this the next time it happens. But I wish more people knew about it,' Freeman said.
A bill moving through the California Legislature would make the process of qualifying for hospital financial assistance easier for some patients. Assembly Bill 1312 would require hospitals to check whether patients are eligible for charity care or discounted payments before sending them a bill.
Specifically, the proposal would require hospitals to presume people enrolled in means-tested programs, such as food stamps and cash assistance, are eligible for financial aid without having to apply. People who are experiencing homelessness or who qualified for assistance from the same hospital in the previous six months would be automatically eligible.
It would also require hospitals to screen patients for eligibility if they are uninsured, enrolled in Medi-Cal with a share of cost or in a Covered California health plan before they are charged.
'We think, especially in light of the cuts that are happening at the federal level, that more and more this is going to be something that is needed in our community and throughout the state,' Sen. Pilar Schiavo, a Santa Clarita Democrat and author of the bill, said during the most recent meeting of the Senate Health Committee. 'This is a … way to ensure that people know upfront that these programs are available to them to prevent the kind of crushing medical debt that unfortunately can really ruin families and their financial situations.'
Sen. Caroline Menjivar, chair of the Senate Health Committee, promised to continue discussions with Schiavo to add screening criteria for moderate-income patients with employer-sponsored insurance. The legislation has to pass the Senate by Sept. 12.
The bill recently went through a round of amendments after negotiations with the hospital lobby. Among the changes is a two-year implementation delay so hospitals can acquire the software necessary to screen patients. If the bill makes it out of the Legislature and is signed by Gov. Gavin Newsom, the earliest it could be enacted is July 2027. The California Hospital Association continues to oppose the bill as it awaits more possible amendments.
Applying for financial assistance
Under California law, hospitals are required to make financial assistance programs, also known as charity care, available to patients who earn up to 400% of the federal poverty level — $62,600 for a single person or $128,600 for a family of four — but also to patients whose medical expenses over the last year have exceeded 10% of their income.
Jan Emerson-Shea, a spokesperson for the California Hospital Association, said some hospitals go beyond that income threshold. Hospitals already promote their financial assistance programs through signs around the hospital, online and on medical bills sent to patients, Emerson-Shea said.
Still, many patients do not know about these programs, surveys and research have shown. A 2023 national survey by Dollar For, a nonprofit organization that helps people apply for financial assistance, found roughly half the patients who are potentially eligible for financial assistance do not apply.
Freeman said she doesn't recall anyone at Stanford Medical Center telling her to apply for charity care, but she did find the application online.
The first time she applied on her own she was denied, she said. She applied a second time, this time with the help from Dollar For. In April 2024 Freeman received a letter from Stanford letting her know that her balance was being waived. She was also able to get back the money she'd already paid.
But the application process was not intuitive, she said. It took help from experts and emails back and forth with the hospital billing department. Yet, given her condition, it's a process she's likely to have to do again.
'The tricky thing is I'm supposed to be very low stress, right? Because I have a heart condition, and the disorder is made worse if your blood pressure is high, if you're getting stressed,' Freeman said. 'Like, I should be very calm, but I'm always thinking about the bills.'
The burden of medical debt
A handful of other states, including Maryland, Illinois and Oregon, have financial assistance screening requirements similar to what California is attempting.
A recent report from Oregon's health agency showed that in the first five months its state law was in effect, hospitals reported challenges — primarily, with the software from third-party vendors that hospitals purchased to help check people's income against publicly available financial data sources. Oregon health officials estimated in January it would take up to nine months before the program ran smoothly.
Los Angeles County is working with the Hospital Association of Southern California to develop a presumptive eligibility tool that would be available to local hospitals, saving them the need to go to third-party vendors.
'There's nothing else like it in the country, and it really solves the problem of, OK, we know this is a good thing to do, but how do we make sure every hospital can do it?' said Dr. Naman Shah, with the Los Angeles County Department of Public Health.
Automatic qualification for financial assistance is critical for preventing medical debt, Shah said.
About 4 in 10 Californians, or an estimated 15 million people, carry medical debt, according to the California Health Care Foundation. That includes hospital bills, but also debt owed to doctors and dental offices. Research has shown that even small amounts of debt can disrupt people's lives and the fear of it often keeps them from seeking timely care.
Many patients who are unaware of financial assistance programs resort to GoFundMe accounts, borrow money from family or friends, or charge their medical bills onto a credit card, said Selene Betancourt, a senior policy manager at the California Pan-Ethnic Health Network, one of the bill sponsors.
'And that makes it even harder to relieve because now it's owned by a credit card company, a bank, and not by the hospitals,' Betancourt said.
Given the pervasive burden of medical debt and the lack of federal action, states and local governments have taken it upon themselves to provide at least some relief.
Last year, for example, the California Legislature passed a law to prevent medical debt from showing up on credit reports. The Biden administration announced a similar effort nationwide last summer, but recently, a judge, with support from the Trump administration, blocked the rule from taking effect.
At a more local level, Los Angeles County earlier this year rolled out a medical debt relief program, eliminating debt for approximately 134,000 residents so far, according to county health officials.
To do this, Los Angeles County partnered with the national nonprofit Undue Medical Debt to purchase debt in bulk at a discounted rate from health systems and collection agencies. The nonprofit runs similar projects in other states.
Debt relief efforts don't fundamentally solve the issue of medical debt, 'But when people are bleeding, they need a band aid,' said Allison Sesso, CEO of Undue Medical Debt. 'There could be future debts for these individuals, but let's remove the ones that are in front of them, so that the hill isn't that much higher for them to climb.'
Sesso's organization last month also announced that a recent donation allowed the group to pay off medical bills for an additional 47,000 Californians, largely in Riverside and San Bernardino counties. Those people should have started to receive notifications at the end of June, according to the nonprofit.
___
This story was originally published by CalMatters and distributed through a partnership with The Associated Press.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
19 minutes ago
- Fast Company
A new FDA-approved device could change how Americans lose weight
Small wearable patches that continuously scan your blood and zap numbers to your smartphone are about to be everywhere. Once the sole domain of people with diabetes, glucose monitors are gaining popularity as a health tracking accessory not that different from an Apple Watch or an Oura Ring. On Wednesday, the FDA approved a glucose monitoring system from the startup Signos for weight management – a first for the tech, which represents a growing corner of the digital wellness space. 'Everyone deserves access to insights that help them live healthier, longer, more vibrant lives,' Signos CEO Sharam Fouladgar-Mercer said in a press release. 'Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen.' Signos designed an app that sets glucose range goals based on individual needs and tailors them over time, encouraging its users to make healthy lifestyle choices to meet them. The app pairs with the Stelo continuous glucose monitor (CGM) sensor patch made by Dexcom, which already sells its devices over the counter for around $100 a month. 'This is the first-ever FDA clearance for a system for weight that isn't a pharmacological intervention, isn't a surgical intervention,' Fouladgar-Mercer told STAT. FDA approval is an expensive, time-intensive process, but obtaining the clearance means a Signos subscription could be covered by HSA and FSA plans and potentially be reimbursed by insurance in the future. Signos sells its plans for $129 for six months, which includes glucose sensors and access to its app, which converts real-time blood sugar data into health insights and tips. The company can also now boast about being the 'world's first and only FDA-cleared app and CGM for weight management and wellness,' which might take it pretty far in a soon-to-be crowded market. As is the case with all technology these days, Signos uses AI to offer personalized recommendations based on the data it logs. Users can also track their food and exercise within the company's app, blending that data with glucose monitoring to make changes to their behavior and diet. Fouladgar-Mercer believes that bariatric surgery patients and some people using GLP-1s for weight loss will want the additional insights possible with the Signos app. The app also offers an alternative non-pharmaceutical path for people looking for new ways to succeed in their weight management goals, and could provide an off-ramp for former GLP-1 users looking to maintain their results with behavioral changes. One piece of the MAHA movement Obsessively quantifying the self right down to your blood sugar levels isn't everyone's cup of tea, but it is a major health goal for the Trump administration. Health and Human Services Secretary Robert F. Kennedy Jr. is championing health tracking devices as part of the Make America Healthy Again movement, which is pursuing disparate health goals from regulating ultra-processed foods to investigating well-studied vaccines, sowing doubt about life-saving shots in the process. 'It's a way… people can take control over their own health. They can take responsibility,' Kennedy said at a recent House Subcommittee on Health hearing. 'They can see, as you know, what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it, and they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives.' Beyond RFK Jr., the U.S. government is poised to have a major glucose tracking booster in the administration. In June, Trump swapped his previous surgeon general nominee out in favor of Dr. Casey Means, a wellness industry figure who co-founded a blood glucose monitoring startup called Levels. Like Signos, that company sells subscription access to an app, pairing custom software with off-the-shelf glucose monitors made by Dexcom. Unlike Signos, Levels is not FDA approved for weight management and is marketed for general wellness. Kennedy, a skeptic of weight loss drugs, has advocated for dietary and behavioral changes over GLP-1s to reverse the most worrying U.S. health trends. 'We think that wearables are a key to the MAHA agenda — Making America Healthy Again,'' Kennedy said. 'My vision is that every American is wearing a wearable within four years.'


WebMD
19 minutes ago
- WebMD
The Real Risks of Turning to AI for Therapy
Aug. 20, 2025 — Whenever Luke W Russell needs to work through something, they turn to ChatGPT. (Luke uses they/them pronouns.) 'I've wept as I've navigated things,' said the Indianapolis filmmaker, who uses the chatbot to pick apart intrusive thoughts or navigate traumatic memories. 'I've had numerous times when what ChatGPT is saying to me is so real, so powerful, and I feel so deeply seen.' Russell's experience reflects a broader, growing reality: Many people are turning to chatbots for mental health support — for everything from managing anxiety and processing grief to coping with work conflicts and defusing marital spats. More than half of adults ages 18-54 — and a quarter of adults 55 and up — say they would be comfortable talking with an AI chatbot about their mental health, according to a 2025 survey by the Harris Poll and the American Psychological Association (APA). The catch: OpenAI's ChatGPT and other chatbots — like Anthropic's Claude and Google's Gemini — are not designed for this. Even AI products promoted as emotional health tools — like Replika, Wysa, Youper, and MindDoc — were not built on validated psychological methods, said psychologist C. Vaile Wright, PhD, senior director of the APA's Office of Health Care Innovation. 'I would argue that there isn't really any commercially approved, AI-assisted therapy at the moment,' said Wright. 'You've got a whole lot of chatbots where there is no research, there's no psychological science, and there are no subject matter experts.' Critics warn that AI's potential for bias, lack of true empathy, and limited human oversight could actually endanger users' mental health, especially among vulnerable groups like children, teens, people with mental health conditions, and those experiencing suicidal thoughts. The growing concern has led to the emergence of the terms 'ChatGPT psychosis' or ' AI psychosis ' — referring to the potential harmful mental health effects of interacting with AI. It's even drawing attention from lawmakers: This month, Illinois enacted restrictions on AI in mental health care, banning its use for therapy and prohibiting mental health professionals from using AI to communicate with clients or make therapeutic decisions. (Similar restrictions have already been passed in Nevada and Utah.) But none of this is stopping people from turning to chatbots for support, especially amid clinician shortages, rising therapy costs, and inadequate mental health insurance coverage. 'People have absolutely reported that experiences with chatbots can be helpful,' said Wright. The Draw of Chatbots for Mental Health Data shows we're facing a massive shortage of mental health workers, especially in remote and rural areas, said psychologist Elizabeth Stade, PhD, a researcher in the Computational Psychology and Well-Being Lab at Stanford University in Stanford, CA. 'Of adults in the United States with significant mental health needs, only about half are able to access any form of treatment. With youth, that number is closer to 75%,' said Jessica Schleider, PhD, a child and adolescent psychologist at Northwestern University in Chicago. 'The provider shortage is clearly contributing to why so many folks are turning to their devices and, now increasingly, to generative AI to fill that gap.' Unlike a therapist, a chatbot is available 24/7. 'When [people] need help the most, it is typically after hours,' said Wright, who suggested the right AI tool could potentially supplement human therapy. 'When it's 2 a.m. and you're in crisis, could this help provide some support?' Probably, she said. Results of the first clinical trial of an AI-generative therapy chatbot showed 'significant, clinically meaningful reductions in depression, anxiety, and eating disorder symptoms' within four to eight weeks, said lead study author Michael V. Heinz, MD, a professor at Dartmouth College's Geisel School of Medicine and faculty affiliate at the Center for Technology and Behavioral Health in Lebanon, New Hampshire. The chatbot — Therabot, developed at Dartmouth — combines extensive training in evidence-based psychotherapy interventions with advanced generative AI. 'We saw high levels of user engagement — six-plus hours on average across the study,' Heinz said. Participants said using Therabot was like talking to a human therapist. But results are early, and more studies are needed, Heinz said. Access and affordability drew Russell to ChatGPT, they said. 'I didn't set out to use ChatGPT as a therapist. I quit therapy in January due to income dropping. I was already using ChatGPT on the regular for work, and then I started using it for personal idea exploration. ... I've never had a therapist who could move as fast as ChatGPT and ignore miscellaneous things,' they said. Perhaps one of the most appealing aspects is that chatbots don't judge. 'People are reluctant to be judged, and so they are often reluctant to disclose symptoms,' said Jonathan Gratch, PhD, professor of computer science and psychology at the University of Southern California, who has researched the topic. One of his studies found that military veterans were more likely to share PTSD symptoms with a virtual chatbot than in a survey. When Chatbots Are Harmful Most people don't know how AI works — they might believe it's always objective and factual, said Henry A. Willis, PhD, a psychologist and professor at the University of Maryland in College Park. But often, the data they're trained on is not representative of minority groups, leading to bias and technology-mediated racism, Willis said. 'We know that Black and brown communities are not adequately reflected in the majority of large-scale mental health research studies,' Willis said. So a chatbot's clinical symptom information or treatment recommendations may not be relevant or helpful to those from minority backgrounds. There's also an impersonal aspect. Chatbots do what's called ecological fallacy, said H. Andrew Schwartz, PhD, associate professor of computer science at Stony Brook University in Stony Brook, NY. They treat scattered comments like random data points, making assumptions based on group-level data that may not reflect the reality of individuals. And who's accountable if something goes wrong? Chatbots have been linked to cases involving suggestions of violence and self-harm, including the death of a teen by suicide. Some chatbots marketed for companionship and emotional support were designed with another incentive: to make money. Wright is concerned that they may unconditionally validate patients, telling them what they want to hear so they stay on the platform — 'even if what they're telling you is actually harmful or they're validating harmful responses from the user.' None of these conversations are bound by HIPAA regulations, either, Wright pointed out. 'So even though they may be asking for personal information or sharing your personal information, they have no legal obligation to protect it.' The Psychological Implications of Forming Emotional Bonds With AI In an opinion article published in April in the journal Trends in Cognitive Sciences, psychologists expressed concern about the long-term implications of forming emotional bonds with AI. Chatbots can replace users' real relationships, crowding out romantic partners, co-workers, and friends. This may mean that individuals begin to 'trust' the opinion and feedback of chatbots over real people, said Willis. 'The ongoing positive reinforcement that can happen instantly from interacting with a chatbot may begin to overshadow any reinforcement from interacting with real people,' who may not be able to communicate as quickly, he said. 'These emotional bonds may also impair people's ability to have a healthy level of skepticism and critical evaluation skills when it comes to the responses of AI chatbots.' Gratch compared it to hunger and food. 'We're biologically wired to seek out food when we get hungry. It is the same with social relationships. If we haven't had a relationship in a while, we may feel lonely, and then that motivates us to go out and reach out to people.' But studies suggest that social interaction with a computer program, like a chatbot, can sate a person's social needs and demotivate them to go out with friends, he said. 'That may have long-term consequences for increased loneliness. For example, research has shown people who compulsively use Facebook tend to be much more lonely.' Counseling with a therapist involves 'a natural curiosity about the individual and their experiences that AI cannot replicate,' Willis said. 'AI chatbots respond to prompts, whereas therapists can observe and ask clinical questions based on one's body language, a synthesis of their history, and other things that may not be conscious to the client — or things the client may not even be aware are important to their mental health well-being.' The Future of AI Therapy "I think there is going to be a future where you have really well-developed [chatbots] for addressing mental health that are scientifically driven and where they are ensuring that there are guardrails in place when somebody is in crisis. We're just not quite there yet,' said the APA's Wright. 'We may get to a place where they're even reimbursed by insurance,' she said. 'I do think increasingly we are going to see providers begin to adopt these technology tools as a way to meet their patients' needs.' But for now, her message is clear: The chatbots are not there yet. 'Ideally, chatbot design should encourage sustained, meaningful interaction with the primary purpose of delivering evidence-based therapy,' said Dartmouth's Heinz. Until then, don't rely on them too heavily, the experts cautioned — and remember, they are not a substitute for professional help.


Medscape
19 minutes ago
- Medscape
GLP-1s Don't Increase Suicide Risk
It's not uncommon for me, when discussing a GLP-1 medication with patients, to have them inquire about the drug's purported risk in increasing suicidal ideation. What has never occurred? Patients asking about the possible benefits of GLP-1 medications to mood and to their decreasing the risk of suicidal ideation. On the face of existing data, that's odd considering there is far more substantial evidence that GLP-1 users see improvements in mood: with no increase —and possibly decreased — risk of suicide. It's not odd, though, when considering things through the lens of how risk is overestimated by the public along with the lens of weight bias where, at least with obesity medications, negative findings — however small, tenuous, or early — tend to be readily internalized and amplified, while positive findings are often minimized and ignored. Where and how did the concern about suicide arise? On July 11, 2023, the European Medicines Agency (EMA) released a statement that, consequent to the Icelandic medicines agency's highlighting three case reports involving suicide among GLP-1 users, they would be investigating further. The EMA's statement rightly and explicitly noted, ' The presence of a signal does not necessarily mean that a medicine caused the adverse event in question .' But much of the media didn't seem to care how premature or unsubstantiated the putative risk, and this story definitely had legs gaining scary coverage in most major media outlets. By way of example, the BBC, in its story headlined Weight-loss jabs investigated for suicide risk , rather than responsibly covering the prematurity of concluding anything at all, chose this quote from the EMA's statement to highlight, ' A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation .' No doubt this sort of reporting is in part why, to this day, patients still recount suicidality as a concern when discussing these medications. But what has happened on this file since the July 2023 initiated investigation of those three purported cases? While nonexhaustive, here's a brief rundown: In April 2024, the EMA's own investigation exonerated GLP-1 medications as a source of increased suicide risk in April 2024. The US FDA also conducted its own investigation and similarly found no ties between GLP-1s and suicide risk. In June 2024. a paper was published demonstrating no increase risk in suicidality among 36,083 adults prescribed GLP-1 medications. In August 2024, a paper was published investigating GLP-1 medications and their impact on 22 neurological and psychiatric outcomes over 12 months. It found no impact among 23,386 GLP-1 users. In September 2024, a paper was published demonstrating no increased risk in suicidality among a cohort of 124,517 adults prescribed GLP-1 medications over a 1-year period. In October 2024, a paper was published demonstrating a 33% reduction in suicide ideation or attempts among 6912 adolescents with obesity for those who initiated treatment with GLP-1s over 3 years of follow-up. In February 2025. a paper was published of a nationwide (France) case-time-control of individuals who had attempted or died by suicide which found no linkage with GLP-1 use. In May 2025. a paper was published demonstrating in a meta-analysis of doubly blind randomized controlled trials that, among the 107,000 patients studied, GLP-1 use was not associated with increased risk of psychiatric adverse events or worsening depressive symptoms relative to placebo. Instead, GLP-1 use was associated with improvements in both physical and mental health-related quality of life. Finally, in June 2025, a paper was published describing a multinational self-controlled case series analysis of suicide or self-harm attempts in Hong Kong, Taiwan, and the United Kingdom that yes, again, demonstrated no increased risk among GLP-1 users and that, compared with the nontreatment period, lower suicide attempt or self-harm risk following GLP-1 treatment was observed, especially after longer periods of treatment. Negative publication bias appears to extend beyond academia into society at large. However, it manifests somewhat differently. The studies receiving the most attention are often those reporting literally negative (ie, adverse) outcomes. In contrast, more rigorous studies that challenge these negative findings, even if publicized, rarely achieve comparable societal penetration or awareness.